Pharmacy News & Analysis
5 articles
Market Mood
Boots Sold to Weston Family in $8.9bn Deal
Boots, a well-known High Street pharmacy and retail chain, has been sold for $8.9 billion (£6.7 billion) to the Weston family of Canada. The deal was confirmed by Wittington Investments, the holding company that acquired Boots from the US private equity firm Sycamore Partners and the Pessina family. Boots operates around 1,800 stores and employs 51,000 people. Galen Weston, chairman of Wittington, expressed plans to upgrade stores and expand healthcare services under the new ownership.
Read More: Boots Sold to Weston Family in $8.9bn Deal
Walgreens (WBA) Retreats as CVS Gains Suburban Pharmacy Market Share
Walgreens (WBA) is experiencing a downturn as CVS Health is reportedly expanding its presence in suburban pharmacies. The shift indicates a growing competitive landscape in the pharmacy sector. This change may influence consumer choices and operational strategies among pharmacy retailers. For investors, the increased competition could affect Walgreens' market share and revenue growth potential, highlighting the importance of monitoring competitive dynamics in the healthcare market.
Read More: Walgreens (WBA) Retreats as CVS Gains Suburban Pharmacy Market Share
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More: CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
Novo Nordisk (NVO) Oral Ozempic and Wegovy Pills Available on Amazon
Novo Nordisk's oral drugs Ozempic and Wegovy are now available for same-day delivery through Amazon's pharmacy kiosks. This event marks a significant development for the availability of Type 2 diabetes treatment options in the U.S. While specific sales figures were not disclosed, this move may enhance Novo Nordisk's market presence and accessibility of its diabetes treatments. The addition to Amazon's service could result in increased volume for both drugs and potentially impact Novo Nordisk's revenue positively.
Read More: Novo Nordisk (NVO) Oral Ozempic and Wegovy Pills Available on Amazon
Amazon (AMZN) Offers Ozempic Pill with Same-Day Delivery
Amazon.com (AMZN) has announced that its pharmacy will stock Novo Nordisk's Ozempic pill for type 2 diabetes, offering same-day delivery in approximately 3,000 locations, expanding to 4,500 by year-end. Patients can order the medication for $149 per month or $25 with insurance. Amazon has been providing GLP-1 medications since 2021 and previously stocked Novo's Wegovy weight-loss drug. The initiative aims to enhance access to medications for customers, with half of U.S. customers eligible for same-day delivery.
Read More: Amazon (AMZN) Offers Ozempic Pill with Same-Day Delivery